El año pasado, Merck & Co Inc generó 31.64B USD en su segmento con mejor rendimiento, Oncology-Keytruda. United States realizó la mayor aportación, representando 36.51B USD el año pasado. Para el último trimestre, Merck & Co Inc reportó unos ingresos de 7.90B USD para el periodo finalizado el 2026-06-30, procedentes del segmento con mejor rendimiento, Oncology-Keytruda. United States aportó los mayores ingresos, alcanzando los 9.37B USD.

Por negocio

Ingresos operativos

Proporción

Anual

Anual

Trimestral

Oncology-Keytruda

Vaccines -Gardasil/Gardasil

Animal Health-Livestock

Other pharmaceutical

Animal Health-Companion Animals

Vaccines -ProQuad/M-M-R II/Varivax

Hospital Acute Care-Bridion

Diabetes-Januvia

Oncology-Alliance revenue - Lynparza

Cardiovascular-Winrevair-US

Oncology-Alliance revenue - Lenvima

Hospital Acute Care- Prevymis

Diabetes-Janumet

Vaccines-Vaxneuvance

Vaccines -Capvaxive

Oncology-Welireg

Vaccines -Pneumovax 23

Oncology-Alliance revenue - Reblozyl

Cardiovascular-Alliance revenue - Adempas

Virology- Lagevrio

Virology-Isentress/Isentress HD

Cardiovascular-Adempas

Hospital Acute Care-Zerbaxa

Virology-Delstrigo-Int

Hospital Acute Care-Dificid

Neuroscience-Belsomra

Cardiovascular-Zetia

Vaccines -RotaTeq

Virology-Pifeltro-US

Cardiovascular-Winrevair-INT

Virology-Pifeltro-INT

Virology-Delstrigo-U.S

Oncology - Keytruda Qlex

Immunology-Simponi

Hospital Acute Care-Noxafil

Immunology-Remicade

Hospital Acute Care-Primaxin

Vaccines -Vaqta

Hospital Acute Care-Invanz

Hospital Acute Care-Cancidas

All Other

Virology- Molnupiravir

Women’s Health-NuvaRing

Diversified Brands-Singulair

Women’s Health-Implanon/Nexplanon

Oncology-Emend

Cardiovascular-Vytorin

Virology-Zepatier

Diversified Brands-Cozaar/Hyzaar

Diversified Brands-Nasonex

Hospital Acute Care-Cubicin

Cardiovascular-Atozet

Diversified Brands-Arcoxia

Diversified Brands-Follistim AQ

Vaccines -Zostavax

Oncology-Temodar

Diversified Brands-Dulera

Diversified Brands-Fosamax

Unallocated

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Oncology-Keytruda

31.64B(49.06%)

29.48B(46.69%)

25.00B(42.73%)

20.94B(36.38%)

17.19B(35.57%)

14.38B(34.79%)

11.08B(28.67%)

7.17B(16.96%)

Vaccines -Gardasil/Gardasil

5.23B(8.11%)

8.58B(13.59%)

8.89B(15.18%)

6.90B(11.98%)

5.67B(11.74%)

3.94B(9.53%)

3.74B(9.66%)

3.15B(7.45%)

Animal Health-Livestock

3.90B(6.04%)

3.46B(5.48%)

3.54B(6.04%)

3.30B(5.73%)

3.29B(6.82%)

2.94B(7.11%)

2.78B(7.20%)

2.63B(6.22%)

Other pharmaceutical

2.92B(4.53%)

2.51B(3.98%)

2.28B(3.90%)

2.25B(3.91%)

2.31B(4.78%)

2.31B(5.59%)

2.88B(7.44%)

4.08B(9.65%)

Animal Health-Companion Animals

2.46B(3.81%)

2.42B(3.83%)

2.29B(3.91%)

2.25B(3.91%)

2.27B(4.70%)

1.76B(4.27%)

1.61B(4.16%)

1.58B(3.74%)

Vaccines -ProQuad/M-M-R II/Varivax

2.45B(3.80%)

2.48B(3.94%)

2.37B(4.05%)

2.24B(3.90%)

2.13B(4.42%)

1.88B(4.54%)

2.27B(5.88%)

1.80B(4.25%)

Hospital Acute Care-Bridion

1.84B(2.85%)

1.76B(2.79%)

1.84B(3.15%)

1.68B(2.93%)

1.53B(3.17%)

1.20B(2.90%)

1.13B(2.92%)

917.00M(2.17%)

Diabetes-Januvia

1.60B(2.49%)

1.33B(2.11%)

2.19B(3.74%)

2.81B(4.89%)

3.32B(6.88%)

3.31B(8.00%)

3.48B(9.01%)

3.69B(8.72%)

Oncology-Alliance revenue - Lynparza

1.45B(2.25%)

1.31B(2.08%)

1.20B(2.05%)

1.12B(1.94%)

988.00M(2.04%)

725.00M(1.75%)

445.00M(1.15%)

188.00M(0.44%)

Cardiovascular-Winrevair-US

1.36B(2.11%)

408.00M(0.65%)

--(--)

Oncology-Alliance revenue - Lenvima

1.05B(1.63%)

1.01B(1.60%)

960.00M(1.64%)

876.00M(1.52%)

704.00M(1.46%)

579.00M(1.40%)

404.00M(1.04%)

149.00M(0.35%)

Hospital Acute Care- Prevymis

978.00M(1.52%)

785.00M(1.24%)

605.00M(1.03%)

428.00M(0.74%)

371.00M(0.77%)

281.00M(0.68%)

165.00M(0.43%)

--(--)

Diabetes-Janumet

940.00M(1.46%)

935.00M(1.48%)

1.18B(2.01%)

1.70B(2.95%)

1.96B(4.06%)

1.97B(4.77%)

2.04B(5.28%)

2.23B(5.27%)

Vaccines-Vaxneuvance

825.00M(1.28%)

808.00M(1.28%)

--(--)

Vaccines -Capvaxive

759.00M(1.18%)

--(--)

Oncology-Welireg

716.00M(1.11%)

509.00M(0.81%)

--(--)

Vaccines -Pneumovax 23

672.00M(1.04%)

711.00M(1.13%)

769.00M(1.31%)

783.00M(1.36%)

893.00M(1.85%)

1.09B(2.63%)

926.00M(2.39%)

908.00M(2.15%)

Oncology-Alliance revenue - Reblozyl

525.00M(0.81%)

371.00M(0.59%)

211.00M(0.36%)

166.00M(0.29%)

--(--)

Cardiovascular-Alliance revenue - Adempas

470.00M(0.73%)

415.00M(0.66%)

366.00M(0.63%)

341.00M(0.59%)

342.00M(0.71%)

281.00M(0.68%)

204.00M(0.53%)

--(--)

Virology- Lagevrio

379.00M(0.59%)

830.00M(1.31%)

1.43B(2.44%)

5.68B(9.88%)

--(--)

Virology-Isentress/Isentress HD

325.00M(0.50%)

394.00M(0.62%)

483.00M(0.83%)

633.00M(1.10%)

768.00M(1.59%)

857.00M(2.07%)

974.00M(2.52%)

1.14B(2.70%)

Cardiovascular-Adempas

312.00M(0.48%)

287.00M(0.45%)

255.00M(0.44%)

238.00M(0.41%)

252.00M(0.52%)

220.00M(0.53%)

215.00M(0.56%)

329.00M(0.78%)

Hospital Acute Care-Zerbaxa

312.00M(0.48%)

252.00M(0.40%)

219.00M(0.37%)

168.00M(0.29%)

-1.00M(--)

130.00M(0.31%)

121.00M(0.31%)

--(--)

Virology-Delstrigo-Int

250.00M(0.39%)

193.00M(0.31%)

--(--)

Hospital Acute Care-Dificid

247.00M(0.38%)

340.00M(0.54%)

302.00M(0.52%)

263.00M(0.46%)

--(--)

Neuroscience-Belsomra

186.00M(0.29%)

222.00M(0.35%)

231.00M(0.39%)

258.00M(0.45%)

319.00M(0.66%)

328.00M(0.79%)

306.00M(0.79%)

260.00M(0.61%)

Cardiovascular-Zetia

178.00M(0.28%)

--(--)

858.00M(2.03%)

Vaccines -RotaTeq

167.00M(0.26%)

263.00M(0.42%)

412.00M(0.70%)

602.00M(1.05%)

807.00M(1.67%)

797.00M(1.93%)

790.00M(2.04%)

728.00M(1.72%)

Virology-Pifeltro-US

111.00M(0.17%)

113.00M(0.18%)

--(--)

Cardiovascular-Winrevair-INT

85.00M(0.13%)

11.00M(0.02%)

--(--)

Virology-Pifeltro-INT

59.00M(0.09%)

50.00M(0.08%)

--(--)

Virology-Delstrigo-U.S

56.00M(0.09%)

--(--)

Oncology - Keytruda Qlex

40.00M(0.06%)

--(--)

Immunology-Simponi

--(--)

543.00M(0.86%)

710.00M(1.21%)

706.00M(1.23%)

825.00M(1.71%)

838.00M(2.03%)

830.00M(2.15%)

893.00M(2.11%)

Hospital Acute Care-Noxafil

--(--)

177.00M(0.28%)

213.00M(0.36%)

238.00M(0.41%)

259.00M(0.54%)

329.00M(0.80%)

662.00M(1.71%)

742.00M(1.75%)

Immunology-Remicade

--(--)

114.00M(0.18%)

187.00M(0.32%)

207.00M(0.36%)

299.00M(0.62%)

330.00M(0.80%)

411.00M(1.06%)

582.00M(1.38%)

Hospital Acute Care-Primaxin

--(--)

212.00M(0.36%)

239.00M(0.42%)

260.00M(0.54%)

250.00M(0.60%)

273.00M(0.71%)

265.00M(0.63%)

Vaccines -Vaqta

--(--)

180.00M(0.31%)

173.00M(0.30%)

179.00M(0.37%)

170.00M(0.41%)

238.00M(0.62%)

--(--)

Hospital Acute Care-Invanz

--(--)

189.00M(0.33%)

202.00M(0.42%)

211.00M(0.51%)

263.00M(0.68%)

496.00M(1.17%)

Hospital Acute Care-Cancidas

--(--)

174.00M(0.30%)

212.00M(0.44%)

214.00M(0.52%)

248.00M(0.64%)

326.00M(0.77%)

All Other

--(--)

23.00M(0.06%)

175.00M(0.45%)

250.00M(0.59%)

Virology- Molnupiravir

--(--)

952.00M(1.97%)

--(--)

Women’s Health-NuvaRing

--(--)

902.00M(2.13%)

Diversified Brands-Singulair

--(--)

708.00M(1.67%)

Women’s Health-Implanon/Nexplanon

--(--)

703.00M(1.66%)

Oncology-Emend

--(--)

522.00M(1.23%)

Cardiovascular-Vytorin

--(--)

497.00M(1.18%)

Virology-Zepatier

--(--)

455.00M(1.08%)

Diversified Brands-Cozaar/Hyzaar

--(--)

454.00M(1.07%)

Diversified Brands-Nasonex

--(--)

376.00M(0.89%)

Hospital Acute Care-Cubicin

--(--)

367.00M(0.87%)

Cardiovascular-Atozet

--(--)

347.00M(0.82%)

Diversified Brands-Arcoxia

--(--)

335.00M(0.79%)

Diversified Brands-Follistim AQ

--(--)

268.00M(0.63%)

Vaccines -Zostavax

--(--)

217.00M(0.51%)

Oncology-Temodar

--(--)

215.00M(0.51%)

Diversified Brands-Dulera

--(--)

214.00M(0.51%)

Diversified Brands-Fosamax

--(--)

209.00M(0.49%)

Unallocated

--(--)

143.00M(0.34%)

Por región

Ingresos operativos

Proporción

Anual

Anual

Trimestral

United States

Europe, Middle East and Africa

Latin America

Asia Pacific (Other than China and Japan)

Other

Japan

China

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

FY2015

FY2014

FY2013

FY2012

FY2011

United States

36.51B(56.16%)

32.28B(50.30%)

28.48B(47.38%)

27.21B(45.89%)

22.43B(46.04%)

19.59B(47.18%)

18.42B(47.08%)

18.21B(43.06%)

17.42B(43.43%)

18.48B(46.42%)

17.52B(44.35%)

17.07B(40.42%)

18.25B(41.44%)

20.39B(43.14%)

20.50B(42.66%)

Europe, Middle East and Africa

14.58B(22.43%)

14.04B(21.88%)

13.25B(22.05%)

14.49B(24.45%)

13.34B(27.39%)

11.55B(27.81%)

10.50B(26.83%)

12.21B(28.88%)

11.48B(28.61%)

10.95B(27.52%)

10.68B(27.03%)

13.17B(31.19%)

13.14B(29.84%)

12.99B(27.48%)

13.78B(28.68%)

Latin America

3.41B(5.25%)

3.46B(5.39%)

3.09B(5.13%)

2.58B(4.36%)

2.21B(4.53%)

1.89B(4.55%)

2.02B(5.15%)

2.42B(5.71%)

2.34B(5.83%)

2.15B(5.41%)

2.82B(7.15%)

3.15B(7.46%)

3.20B(7.27%)

--(--)

Asia Pacific (Other than China and Japan)

2.98B(4.59%)

3.06B(4.77%)

3.23B(5.36%)

3.61B(6.10%)

2.41B(4.94%)

2.11B(5.09%)

2.13B(5.43%)

2.91B(6.88%)

4.34B(10.81%)

3.92B(9.84%)

3.82B(9.67%)

3.95B(9.35%)

3.85B(8.73%)

--(--)

Other

2.88B(4.43%)

2.56B(3.99%)

2.10B(3.50%)

2.57B(4.33%)

1.22B(2.51%)

1.03B(2.47%)

1.27B(3.26%)

1.15B(2.72%)

1.42B(3.54%)

1.46B(3.66%)

1.99B(5.03%)

1.42B(3.36%)

1.55B(3.53%)

8.78B(18.58%)

8.94B(18.60%)

Japan

2.71B(4.17%)

3.28B(5.11%)

3.16B(5.26%)

3.63B(6.12%)

2.73B(5.60%)

2.60B(6.27%)

2.61B(6.67%)

3.21B(7.59%)

3.12B(7.78%)

2.85B(7.15%)

2.67B(6.77%)

3.47B(8.22%)

4.04B(9.18%)

5.10B(10.79%)

4.83B(10.06%)

China

1.94B(2.98%)

--(--)

2.18B(5.16%)

--(--)

China

--(--)

5.49B(8.56%)

6.80B(11.31%)

5.19B(8.76%)

4.38B(8.99%)

2.75B(6.63%)

2.18B(5.57%)

--(--)